 |
| mupirax |
GLOBAL NAPI
• DERMA mupirax Mupirocin 2%
ompositior Each gram of Mupirax ointment contains 20 mg mupirocin in a white, translucent, water-soluble, polyethylene glycol base. Mupirax, mupirocin, is a topical antibacterial agent which inhibits bacterial protein synthesis & RNA synthesis by binding to isoleucyl transfer-RNA synthetase.
It is mainly active against aerobic isolates of Staphylococcus aureus (including Methicillin-resistant & B-lactamase producing strains), S. epidermidis, S. saprophyticus & Streptococcus pyogenes are susceptible to mupirocin.
It is also active against gram-negative organisms, such as Escherichia coli & Haemophilus influenzae. Mupirax shows no cross-resistance with other antibiotics. Mupirax has shown no measurable systemic absorption.
Its penetration into deeper epidermal & dermal layers of the skin is enhanced in traumatised skin & under occlusive dressings.
1- Treatment of primary & secondary superficial skin infections.
2- Treatment of various topical bacterial infections, such as impetigo, folliculitis & furunculosis caused by S. aureus (including Methicillin-resistant Staphylococcus aureus (MRSA), betahemolytic streptococcus, S. pyogenes. 3- Treatment of burn wound infections caused by MRSA infections.
4- Treatment of infected wounds & lacerations.
Mupirocin is usually well tolerated but local reactions such as burning, stinging, & itching may occur after its application to the skin. MbO GLOBAL NAPI PHARMACEUTICALS
EGYPT
• DERMA mupirax Mupirocin 2%
ompositior Each gram of Mupirax ointment contains 20 mg mupirocin in a white, translucent, water-soluble, polyethylene glycol base. Mupirax, mupirocin, is a topical antibacterial agent which inhibits bacterial protein synthesis & RNA synthesis by binding to isoleucyl transfer-RNA synthetase.
It is mainly active against aerobic isolates of Staphylococcus aureus (including Methicillin-resistant & B-lactamase producing strains), S. epidermidis, S. saprophyticus & Streptococcus pyogenes are susceptible to mupirocin.
It is also active against gram-negative organisms, such as Escherichia coli & Haemophilus influenzae. Mupirax shows no cross-resistance with other antibiotics. Mupirax has shown no measurable systemic absorption.
Its penetration into deeper epidermal & dermal layers of the skin is enhanced in traumatised skin & under occlusive dressings.
1- Treatment of primary & secondary superficial skin infections.
2- Treatment of various topical bacterial infections, such as impetigo, folliculitis & furunculosis caused by S. aureus (including Methicillin-resistant Staphylococcus aureus (MRSA), betahemolytic streptococcus, S. pyogenes. 3- Treatment of burn wound infections caused by MRSA infections.
4- Treatment of infected wounds & lacerations.
Mupirocin is usually well tolerated but local reactions such as burning, stinging, & itching may occur after its application to the skin. MbO GLOBAL NAPI PHARMACEUTICALS
EGYPT
No comments:
Post a Comment